Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Diabetes Reviews
  4. Volume 21, Issue 2
  5. Article
Volume 21, Issue 2
  • ISSN: 1573-3998
  • E-ISSN: 1875-6417

Abstract

Background

Myocardial infarction (MI) is a leading cause of death worldwide, particularly in patients with diabetes mellitus (DM). Tirofiban, a platelet GP IIb/IIIa receptor inhibitor, has shown promise as adjunctive therapy in the emergency management of MI in diabetic patients. However, a comprehensive understanding of its use, efficacy, safety, and limitations in this patient population is necessary to optimize treatment strategies and improve patient outcomes.

Methodology

This review article utilized a systematic approach to gather relevant research articles, clinical trials, and studies on the use of tirofiban in the therapy of MI in diabetic patients. Databases, such as PubMed and Google Scholar, were extensively searched using specific keywords related to tirofiban, MI, DM, STEMI, and antiplatelet therapy. The collected data were carefully examined, summarized, and analyzed to provide an extensive overview of using tirofiban in the management of MI in diabetic individuals.

Results

The analysis of the gathered literature revealed that tirofiban has demonstrated efficacy in improving clinical outcomes, reducing myocardial ischemia-reperfusion injury, and promoting early recovery of heart function in diabetic patients with MI undergoing percutaneous coronary intervention. The fast on- and off-rate and dose-dependent effect of the drug on platelet aggregation contribute to its effectiveness. However, caution should be exercised due to the potential risk of tirofiban-associated thrombocytopenia. Clinical trials and studies have provided evidence-based dosing guidelines, enabling the safe and effective administration of tirofiban in this patient population.

Conclusion

Tirofiban, a platelet GP IIb/IIIa receptor inhibitor, shows promise as adjunctive therapy in the emergency management of MI in diabetic patients. It has demonstrated efficacy in improving clinical outcomes, reducing myocardial ischemia-reperfusion injury, and promoting early recovery of heart function. However, healthcare providers should be cautious regarding the potential risk of tirofiban-associated thrombocytopenia. Further research is needed to optimize dosing guidelines, evaluate long-term safety, and fully understand the benefits and limitations of tirofiban in this patient population. The comprehensive insights provided in this review aim to enhance treatment strategies and improve patient outcomes in the emergency management of MI in diabetic individuals.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cdr/10.2174/0115733998276043231225152605
2024-01-25
2024-11-19

  • From This Site

    /content/journals/cdr/10.2174/0115733998276043231225152605
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. SchrörK. WeberA.A. Comparative pharmacology of GP IIb/IIIa antagonists.J. Thromb. Thrombolysis2003152718010.1023/B:THRO.0000003308.63022.8d 14618072
     [Google Scholar]
  2. TopolE.J. ByzovaT.V. PlowE.F. Platelet GPIIb-IIIa blockers.Lancet1999353914822723110.1016/S0140‑6736(98)11086‑3 9923894
     [Google Scholar]
  3. BarlésiF. DoddoliC. TorreJ.P. Comparative prognostic features of stage IIIAN2 and IIIB non-small-cell lung cancer patients treated with surgery after induction therapy.Eur. J. Cardiothorac. Surg.200528462963410.1016/j.ejcts.2005.06.018 16125957
     [Google Scholar]
  4. National Center for Biotechnology InformationAvailable at: https://www.ncbi.nlm.nih.gov/books/NBK532281/ Accessed on April 15, 2023
  5. XuX. ChenP. WangJ. FengJ. ZhouH. LiX. Meta-analysis of glycated hemoglobin and type 2 diabetes mellitus based on a longitudinal cohort from China.World J. Diabetes201561312461254 26468341
     [Google Scholar]
  6. IbanezB. JamesS. AgewallS. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation.Eur. Heart J.201839211917710.1093/eurheartj/ehx393 28886621
     [Google Scholar]
  7. GongJ. ShangJ. YuH. Tirofiban for acute ischemic stroke: Systematic review and meta-analysis.Eur. J. Clin. Pharmacol.202076447548110.1007/s00228‑019‑02817‑8 31900544
     [Google Scholar]
  8. WangH. FengM. Influences of different dose of tirofiban for acute ST elevation myocardial infarction patients underwent percutaneous coronary intervention.Medicine20209923e2040210.1097/MD.0000000000020402 32501985
     [Google Scholar]
  9. Center for Drug Evaluation and ResearchFood and Drug AdministrationAvailable from: https://www.fda.gov/drugs/drug-approvals-and-databases/drugsfda-data-files Accessed July 12, 2023
     [Google Scholar]
  10. LeonB.M. MaddoxT.M. Diabetes and cardiovascular disease: Epidemiology, biological mechanisms, treatment recommendations and future research.World J. Diabetes20156131246125810.4239/wjd.v6.i13.1246 26468341
     [Google Scholar]
  11. Mosby’s dictionary of medicine, nursing & health.US Elsevier Health2016Available at: https://www.us.elsevierhealth.com/mosbys-dictionary-of-medicine-nursing-health-professions-9780323639149.html Accessed on July 12, 2023
     [Google Scholar]
  12. TangX. LiR. MaL. ZhangT. Application of tirofiban in patients with acute myocardial infarction complicated with diabetes and undergoing emergency interventional therapy.Pak. J. Med. Sci.2022381172178 35035421
     [Google Scholar]
  13. GharianiA. MosratiH. Ben AbdessalemM.A. Prognostic impact of diabetes mellitus on patients managed by urgent percutaneous coronary intervention.Tunis. Med.20221002143148 35852249
     [Google Scholar]
  14. Cardiovascular disease and risk management: Standards of medical care in diabetes.Diabetes Care202245Suppl. 1S144S17410.2337/dc22‑S010 34964815
     [Google Scholar]
  15. AjjanR.A. KietsirirojeN. BadimonL. Antithrombotic therapy in diabetes: Which, when, and for how long?Eur. Heart J.202142232235225910.1093/eurheartj/ehab128 33764414
     [Google Scholar]
  16. ParizoJ. MahaffeyK.W. Diabetes and heart failure post-acute myocardial infarction: Important associations and need for evidence-based interventions.Eur. J. Prev. Cardiol.202027171887188910.1177/2047487320904232 32090588
     [Google Scholar]
  17. WangM.T. LinS.C. TangP.L. The impact of DPP-4 inhibitors on long-term survival among diabetic patients after first acute myocardial infarction.Cardiovasc. Diabetol.20171618910.1186/s12933‑017‑0572‑0 28697774
     [Google Scholar]
  18. GhonimA.A. MostafaA. EmaraA. AlgazzarA.S. QutubM.A. Clinical outcome of intracoronary versus intravenous high-dose bolus administration of tirofiban in diabetic patients undergoing primary percutaneous coronary intervention.Cardiovasc. J. Afr.201930528528910.5830/CVJA‑2019‑027 31194213
     [Google Scholar]
  19. SimekS. MotovskaZ. HlinomazO. The effect of diabetes on prognosis following myocardial infarction treated with primary angioplasty and potent antiplatelet therapy.J. Clin. Med.202098255510.3390/jcm9082555 32781780
     [Google Scholar]
  20. Gurk-TurnerC. Glycoprotein IIb/IIIa receptor antagonists: A review of the pivotal trials.Proc. Bayl. Univ. Med. Cent.200013217918210.1080/08998280.2000.11927665 16389375
     [Google Scholar]
  21. van ’t HofA. HammC. RasoulS. GupthaS. PaoliniJ. ten BergJ. Ongoing tirofiban in myocardial infarction evaluation (On-TIME) 2 trial: Rationale and study design.EuroIntervention20073337138010.4244/EIJV3I3A67 19737720
     [Google Scholar]
  22. XuZ. RuiY.N. HaganJ.P. KimD.H. Intracranial aneurysms: Pathology, genetics, and molecular mechanisms.Neuromolecular Med.201921432534310.1007/s12017‑019‑08537‑7 31055715
     [Google Scholar]
  23. AdamouA. AlexandrouM. RothC. ChatziioannouA. PapanagiotouP. Endovascular treatment of intracranial aneurysms.Life202111433510.3390/life11040335
     [Google Scholar]
  24. van GijnJ. KerrR.S. RinkelG.J.E. Subarachnoid haemorrhage.Lancet2007369955830631810.1016/S0140‑6736(07)60153‑6 17258671
     [Google Scholar]
  25. SamaniegoE.A. GibsonE. NakagawaD. Safety of tirofiban and dual antiplatelet therapy in treating intracranial aneurysms.Stroke Vasc. Neurol.201941364210.1136/svn‑2018‑000192 31105977
     [Google Scholar]
  26. Cerebrovascular disease: Causes, symptoms, and treatment.Medical News TodayAvailable at: https://www.medicalnewstoday.com/articles/184601 Accessed July 13, 2023
     [Google Scholar]
  27. SchwarzM. MeadeG. StollP. Conformation-specific blockade of the integrin GPIIb/IIIa: A novel antiplatelet strategy that selectively targets activated platelets.Circ. Res.2006991253310.1161/01.RES.0000232317.84122.0c 16778135
     [Google Scholar]
  28. IshikawaT. ShimizuM. KoharaS. TakizawaS. KitagawaY. TakagiS. Appearance of WBC-platelet complex in acute ischemic stroke, predominantly in atherothrombotic infarction.J. Atheroscler. Thromb.201219549450110.5551/jat.10637 22659534
     [Google Scholar]
  29. RadkeP.W. JanssensU. SchwarzE.R. vom DahlJ. Therapeutic dissolution of an intracoronary thrombus by prolonged intravenous platelet glycoprotein IIb/IIIa antagonism.J. Invasive Cardiol.19991111679681 10745462
     [Google Scholar]
  30. SeitzR.J. HamzaviM. JunghansU. RinglebP.A. SchranzC. SieblerM. Thrombolysis with recombinant tissue plasminogen activator and tirofiban in stroke: Preliminary observations.Stroke20033481932193510.1161/01.STR.0000080535.61188.A6 12829861
     [Google Scholar]
  31. RahmanN. JafaryF.H. Vanishing platelets: Rapid and extreme tirofiban-induced thrombocytopenia after percutaneous coronary intervention for acute myocardial infarction.Tex. Heart Inst. J.2010371109112 20200641
     [Google Scholar]
  32. RawalaM.S. AhmedA.S. PosinaK. SundaramV. Tirofiban induced thrombocytopenia: A rare but severe adverse effect.J. Community Hosp. Intern. Med. Perspect.202010217117310.1080/20009666.2020.1747783 32850060
     [Google Scholar]
  33. LiY. XuQ. GuoX. Thromboembolic events secondary to tirofiban-induced thrombocytopenia being treated with thrombopoietin: A case report.Exp. Ther. Med.20161221177118010.3892/etm.2016.3439 27446339
     [Google Scholar]
  34. DasguptaH. BlankenshipJ.C. WoodG.C. FreyC.M. DemkoS.L. MenapaceF.J. Thrombocytopenia complicating treatment with intravenous glycoprotein IIb/IIIa receptor inhibitors: A pooled analysis.Am. Heart J.2000140220621110.1067/mhj.2000.107554 10925331
     [Google Scholar]
  35. BougieD.W. WilkerP.R. WuitschickE.D. Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPIIb/IIIa.Blood200210062071207610.1182/blood.V100.6.2071 12200368
     [Google Scholar]
  36. WalshR.D. BarrettK.M. AguilarM.I. Intracranial hemorrhage following neuroendovascular procedures with abciximab is associated with high mortality: A multicenter series.Neurocrit. Care2011151859510.1007/s12028‑010‑9338‑1 20169473
     [Google Scholar]
  37. KumarA. HerrmannH.C. Tirofiban: An investigational plateletglycoprotein IIb/IIIa receptor antagonist.Expert Opin. Investig. Drugs1997691257126710.1517/13543784.6.9.1257 15991900
     [Google Scholar]
/content/journals/cdr/10.2174/0115733998276043231225152605
Loading
Examining the Efficacy, Safety, and Future Prospects of Tirofiban in Managing Myocardial Infarction among Diabetic Patients
Curr. Diabetes Rev. 21, E250124226177 (2025); https://doi.org/10.2174/0115733998276043231225152605
/content/journals/cdr/10.2174/0115733998276043231225152605
/content/journals/cdr/10.2174/0115733998276043231225152605
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): antiplatelet therapy; diabetes mellitus; myocardial infarction; STEMI; thrombocytopenia; Tirofiban

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test